AGEN - Agenus Inc logo

AGEN

Agenus Inc

Agenus Inc develops immunotherapies targeting cancer and infectious diseases, offering platforms for human monoclonal antibodies and vaccine adjuvants. Key products include the Balstilimab antibody and various checkpoint modulators in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 20 years ago โ†’$37today

Score Overview

1 Year
Score
Net Growth804x
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth16.20%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.7
Net Growth486.87%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-55.12%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth172.89%
Net Trend60%
Net Income Consistency
Rev Growth487.84%
Rev Trend60%
Revenue Consistency
20 Years
Score4.6
Net Growth278.41%
Net Trend50%
Net Income Consistency
Rev Growth191x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth298.08%
Net Trend50%
Net Income Consistency
Rev Growth299x
Rev Trend58%
Revenue Consistency

See the full market ranking โ†’

Agenus Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 88M to $ 114M and net income went from -$ 180M to $ 115K. Revenue increased in 3 of those 5 years; net income in 3.

Across Agenus Inc's full reported history, from 2000 to 2025, revenue grew from $ 442.63K to $ 114M and net income went from -$ 46M to $ 115K. Revenue increased in 58% of the years measured; net income in 50%.

Agenus Inc currently holds a 20-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 6.90โ€”
1 Year2025-08-12
$ 4.8143.45%
5 Years2021-08-12
$ 116.78-94.09%
10 Years2016-08-12
$ 122.07-94.35%
20 Years2006-08-11
$ 187.23-96.31%
All Time2000-02-04
$ 7.23K-99.90%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 132M$ 92M$ 18M
2025$ 114M$ 115K$ 2M
2024$ 103M-$ 227M$ 40M
2023$ 156M-$ 245M$ 76M
2022$ 98M-$ 220M$ 193M
2021$ 295M-$ 23M$ 306M
2020$ 88M-$ 180M$ 99M
2019$ 150M-$ 107M$ 61M
2018$ 36M-$ 159M$ 53M
2017$ 42M-$ 120M$ 60M
2016$ 22M-$ 126M$ 76M
2015$ 24M-$ 87M$ 171M
2014$ 6M-$ 42M$ 40M
2013$ 3M-$ 30M$ 27M
2012$ 15M-$ 11M$ 21M
2011$ 2M-$ 23M$ 10M
2010$ 3M-$ 21M$ 19M
2009$ 3M-$ 30M$ 30M
2008$ 2M-$ 28M$ 34M
2007$ 5M-$ 36M$ 18M
2006$ 692.13K-$ 51M$ 40M
2005$ 629.98K-$ 74M$ 61M
2004$ 707.07K-$ 56M$ 86M
2003$ 4M-$ 65M$ 89M
2002$ 3M-$ 55M$ 58M
2001$ 4M-$ 73M$ 60M
IPO2000$ 442.63K-$ 46M$ 99M

Explore beyond AGEN

You're looking at Agenus Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies